Bayer appoints Sue Ann Pentecost as head of U.S. pharmaceutical communications

Sue Ann Pentecost has been named by Whippany-based Bayer as the new vice president, head of pharmaceutical communications in the U.S., according to a Monday announcement.

Pentecost will report directly to Beth Roden, senior vice president, head of communications, for Bayer U.S., and head of communications, Bayer Consumer Health. Pentecost succeeds Lori Moore, who is retiring at the end of May.

Pentecost joined Bayer in 2022 as head, external communications, for U.S. Pharmaceuticals, responsible for above-brand efforts to support business priorities. Her role expanded to include U.S. Oncology communications, where she drove creative campaigns in the prostate cancer space. More recently, Pentecost has played an integral role on key corporate media relations initiatives to continue building Bayer’s reputation in the U.S. market.

In her new role, Pentecost will be responsible for developing and executing fully integrated programs to advance the reputation of Bayer overall with an emphasis on the U.S. Pharmaceuticals business and brands.

“I am delighted to have Sue Ann step into this role. She has a breadth of experience across all facets of communications, is a valued leader and colleague, and brings innovative thinking that will be key as we help position Bayer for long-term success,” Roden said. “I also want to sincerely thank Lori Moore for her dedicated service to the company and for her strong leadership during her time at Bayer. She has been instrumental in elevating our U.S. pharma communications function to support the business during a time of significant transformation.”

Pentecost has more than 25 years’ experience in executive, external and internal communications, with a focus in health care. Prior to joining Bayer, she spent 14 years at PPD Inc., now part of Thermo Fisher Scientific, where she held a variety of leadership roles across communications and marketing.

“Communication is a critical function, and I’m honored to take on this leadership role during such a pivotal time of growth for Bayer’s U.S. Pharmaceuticals business,” Pentecost said. “Bringing innovative medicines to market is at the heart of what we do. I look forward to communicating our important story to patients, physicians and providers, as well as colleagues throughout the United States.”